Date | Title | Description | |
---|---|---|---|
23 Feb 2022 | On business and financial situation | The Company releases the press release related to the full year 2021 financial results | Download |
23 Feb 2022 | On business and financial situation | The Company releases the full year 2021 financial results presentation | Download |
23 Feb 2022 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
22 Feb 2022 | On buy-back programmes | ROVI reports the end of the share buy-back programme, effective as of 3 November 2021, and the launching of a new share buy-back programme, effective as of 23 February 2022. | Download |
16 Feb 2022 | On business and financial situation | Moderna and ROVI announced that they expand their long-term collaboration for the manufacture of mRNA medicines over the next ten years | Download |
Pages
Date | Title | Description | |
---|---|---|---|
12 Mar 2024 | On business and financial situation | ROVI, Insud Pharma and Innvierte (CDTI) create a company for the research and development of advanced therapies | Download |
08 Mar 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 1 March and 7 March 2024 | Download |
07 Mar 2024 | On corporate transactions | ROVI notes the recent press speculation and informs about the assessment of potential strategic alternatives | Download |
01 Mar 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 23 February and 29 February 2024 | Download |
27 Feb 2024 | Annual Financial Reports and Audit Reports | The Company submits the 2023 Annual Financial Report | Download |
Pages
Date | Title | Description | |
---|---|---|---|
26 Feb 2019 | Información sobre resultados | ROVI releases the presentation related to the full year 2018 results | Download |
26 Feb 2019 | Información sobre resultados | ROVI releases the press release related to the full year 2018 results | Download |
15 Feb 2019 | Others on business performance and financial information | ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets | Download |
09 Jan 2019 | Others on business performance and financial information | ROVI informs about the adquisition of Falithrom® for the German market | Download |
08 Jan 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the fourth quarter of 2018 | Download |